<DOC>
	<DOCNO>NCT02000440</DOCNO>
	<brief_summary>This single-arm , multicenter , open-label Phase II , proof-of-mechanism study evaluate efficacy , safety , tolerability pharmacokinetics losmapimod approximately 21 subject primary ( idiopathic ) focal segmental glomerulosclerosis ( FSGS ) substantive proteinuria indicate Urinary protein/creatinine Up/c ratio &gt; =2 gram/gram ( g/g ) 24 hr urine protein &gt; =2 g/day . Losmapimod orally administer twice daily 24-week treatment phase follow 12-week follow-up safety relapse assessment .</brief_summary>
	<brief_title>A Phase II , Repeat Dose , Proof Mechanism Study Losmapimod Reduce Proteinuria Patients With Focal Segmental Glomerulosclerosis ( FSGS )</brief_title>
	<detailed_description />
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<criteria>Subject 18 70 year age inclusive . Subject clinical diagnosis primary ( idiopathic ) focal segmental glomerulosclerosis ( FSGS ) verify renal biopsy . This must confirm independent review histopathology report and/or biopsy specimen ( ) study central pathologist . Subject substantive proteinuria , indicate spot Up/c &gt; =2g/g 24 hour urine total protein &gt; =2g/day . A female subject eligible participate nonchildbearing potential ; criterion consider 'nonchildbearing potential ' describe protocol . A female subject eligible participate childbearing potential . Females childbearing potential must agree use two approve contraception method list protocol 14 day first dose study drug 30 day last dose study drug . Only females childbearing potential negative pregnancy test , determine serum human chorionic gonadotropin ( hCG ) test screen urine hCG test prior dose baseline visit study indicate time , administer losmapimod . Subject capable give write informed consent , include compliance requirement restriction list consent form willing able return study visit . Subject receive live attenuated vaccine within 6 week first study treatment . Subject collapse FSGS lesion . Subject secondary FSGS renal impairment condition FSGS . Causes secondary FSGS include limit : Drugs toxin : Analgesics , heroin , cocaine pamidronate ; Infectious parasitic disease : Hepatitis B , Hepatitis C , HIV ( know HIVAssociated Nephropathy ) , parvovirus ; Adaptive structuralfunctional response likely mediate glomerular hypertrophy/hyperfiltration : Hemodynamic factor With reduced renal mass : solitary kidney , renal allograft , renal dysplasia , renal agenesis , oligomeganephronia , segmental hypoplasia , vesicoureteric reflux ; Hemodynamic cause Without reduce renal mass : sickle cell nephropathy , congenital cyanotic heart disease , hypertension ; Malignancies : Lymphomas malignancy ; skin cervical cancer consult medical monitor ; Diabetic Nephropathy ; Other form glomerular nephropathy : focal proliferative glomerulonephritis ( IgA nephropathy , lupus , nephritis , pauciimmune focal necrotizing crescentic glomerulonephritis ) , hereditary nephritis , hypertensive arterionephrosclerosis , membranous glomerulopathy , thrombotic microangiopathies ; Miscellaneous : Alport syndrome , sarcoidosis , radiation nephritis ; Genetic form FSGS ( e.g . patient know carry FSGS cause genetic mutation ) . History congestive heart failure . History diabetes mellitus type 1 2 . History major organ transplant ( e.g. , heart , lung , kidney , liver ) hematopoietic stem cell/marrow transplant . Clinically significant systemic illness infection within last 28 day ( e.g . chronic persistent acute infection ) likely result deterioration subject 's condition affect subject 's safety study . Any condition situation , include clinically significant abnormality screen laboratory assessment ( related disease ) , opinion Investigator could confound result study put subject undue risk . History sensitivity intolerance study treatment ( i.e . losmapimod ) , history drug allergy opinion Investigator GSK Medical Monitor contraindicate participation . Estimated GFR &lt; 45 milliliter ( mL ) /minutes ( min ) /1.73m^2 ( use 4variable Modification Diet Renal Disease [ MDRD ] formula ) screening . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; = 2xUpper Limit Normal ( ULN ) ; alkaline phosphatase bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Single QTc value obtain baseline ECG : QTc &gt; =450 millisecond ( msec ) ( machine manual overread ) ; QTc &gt; =480 msec subject Bundle Branch Block . If single QTc abnormal , average QTc value triplicate electrocardiogram ( ECGs ) obtain ( separate least 5 min ) utilize determine eligibility . Hypertensive define blood pressure ( BP ) &gt; 140/90 millimetre mercury ( mmHg ) end screening : If single BP measurement 140 mmHg systolic 90 mmHg diastolic , BP measurement repeat . The subject must 2 consecutive BP reading less 140 mmHg systolic 90 mmHg diastolic , measurement must separate least 15 minute , eligible participation study . A female subject pregnant nursing . Positive serology chronic infection : historically positive Human Immunodeficiency Virus ( HIV ) test test positive screening HIV ; serologic evidence Hepatitis B ( HB ) infection base result test hepatitis B surface antigen ( HBsAg ) , anti hepatitis B core antigen ( HBc ) , positive test Hepatitis C antibody confirm HCV RNA . If HCV RNA available , positive test Hepatitis C antibody alone would exclusionary . Subject donate blood blood product excess 500 mL within 56 day period prior first dose current study . Participation : The subject participate clinical trial previously receive losmapimod ; subject participate clinical trial receive investigational product 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) prior first dose current study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GW856553</keyword>
	<keyword>Focal segmental glomerulosclerosis ( FSGS )</keyword>
	<keyword>p38 mitogen-activated protein kinase ( MAPK ) inhibitor</keyword>
	<keyword>losmapimod</keyword>
	<keyword>nephrotic syndrome</keyword>
</DOC>